Now, says Dr. Levitt, Insilico Medicine is using AI to create an entirely new AI-driven drug discovery pipeline from A to Z. AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, have announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. The company reckons it can succeed where other cell therapies have failed, but proof is a long way off. We also use them to share usage information with our partners. Accessibility Cancer Lett. A, ELISA of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by CD73. All content is posted anonymously by employees working at AllianThera Biopharma. Careers. General. Can your gut microbes tell you how old you really are? Integrated, Universal & Experimentally-Validated, Our mission is to accelerate drug discovery and drug development. Search Jobs. Design Therapeutics. However, STING activation was restrained by ectonucleosidase CD73, which is induced in MET-amplified, EGFR-TKI-resistant cells. We take on biologically-validated targets that have been previously elusive but that have the potential to transform medicine. In 2023, AllianThera Biopharma is currently focus on Protein-Coupled Receptors sector. Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition - Add Awards PMID: 36066413 DOI: 10.1158/0008-5472.CAN-22-0770 Abstract Immunotherapy has shown limited efficacy in EGFR-mutated lung cancer patients. AllianThera Biopharma 5 jobs. By using this site, you agree that we may store and access cookies on your device. National Library of Medicine AllianThera Biopharma Updated February 18, 2023 Popular Jobs on Glassdoor Mechanical Engineer Jobs IT Jobs Human Resource Jobs Healthcare Jobs Graphic Designer Jobs Account Executive Jobs Registered Nurse Jobs Pharmaceutical Sales Jobs Guide to Getting Your First Job Find a Great First Job to Jumpstart Your Career How to Get a Job 2023 SignalHire.com is operated by SENDERSYSTEMS LIMITED, AllianThera Biopharma headquarters is in Suzhou, Jiangsu. Unauthorized use of these marks is strictly prohibited. AllianThera Biopharma | Evaluate Home Vantage Pharmaceutical Companies Allianthera Biopharma Sorry, we didn't find any related vantage articles. Shi P, Oh YT, Zhang G, Yao W, Yue P, Li Y, Kanteti R, Riehm J, Salgia R, Owonikoko TK, Ramalingam SS, Chen M, Sun SY. The .gov means its official. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone AllianThera Biopharma lead by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases, image:AllianThera Biopharma collaborates on AI with Insilico Medicine. alicia@thrustsc.com. Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. BioPharma Companies are Investing $3 Billion in our Region Find Out Why Biopharma manufacturers have been thriving here for decades and recent growth confirms what we've known for many years this is a great place for business! official website and that any information you provide is encrypted Here, we discover that MET amplification, the most common mechanism of resistance to third-generation EGFR tyrosine kinase inhibitors (TKI), activates tumor cell STING, an emerging determinant of cancer immunogenicity (1). N Engl J Med 2018;378:11325. Insilico Medicine unveils its fully updated Pharma.AI platform in virtual event, Saudi Ministry of Investment and Insilico Medicine sign agreement to expand region's biotechnology capabilities, Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million, Insilico Medicine identified multiple new targets for amyotrophic lateral sclerosis (ALS) using its AI-driven target discovery engine, Insilico Medicine appoints Dr. Feng Ren as co-CEO, Insilico Medicine Raises $60 Million in Series D Financing to Advance Pipeline and Launch AI-powered Drug Discovery Robotics Laboratory, Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment, CB Insights Again Names Insilico Medicine One of the Top 100 AI Companies in the World, Insilico Medicine expands synthetic lethality portfolio with nomination of a preclinical candidate targeting MAT2A for the treatment of MTAP-deleted cancers, Insilico Medicine Announces Advancement of Its Preclinical Candidate for USP1 Synthetic Lethality Target to IND-enabling Studies for Various Oncological Disorders, Insilico Medicine Applauded by Frost & Sullivan for Enabling Rapid and Cost-Effective Drug Discovery and Development with Its Pharma.AI Platform, Fosun Pharma and Insilico Medicine Announce a Strategic, AI-driven Drug Discovery and Development Collaboration to Jointly Advance Multiple Targets, Insilico Medicine to Present at the 40th Annual J.P. Morgan Healthcare Conference, Insilico Medicine Announces the Nomination of Two Preclinical Candidates for PHD2, 12 Months After Program Initiation, Insilico Medicine Appoints Business Leader, Michelle Chen, as Chief Business Officer, Insilico Medicine Appoints Nirav Jhaveri as Chief Financial Officer, PAQ Therapeutics Announces Collaboration with Insilico Medicine to Develop Novel Therapies through Autophagy-Dependent Degradation, Huadong Medicine and Insilico Medicine enter co-development partnership to advance oncology drug discovery by hitting undruggable targets, Insilico Medicine and University of Cambridge Announce a Collaboration on Target Identification for Human Diseases Linked to Protein Liquid-liquid Phase Separation, Insilico Medicine Appoints Dr. Robert Spiegel, MD, FACP, as acting Chief Medical Officer (CMO) to Oversee the Clinical Translation of its Preclinical Pipeline Assets, Insilico Medicine Collaborates with Gray Matter to Fight Age-related Cognitive Decline, Insilico Medicine and 4B Technologies Announce Strategic Collaboration in Advancing Novel Drug Discovery for Neurodegenerative Diseases, The Former Director of the Center for Drug Evaluation and Research at FDA and R&D Leader at Amgen, Steven Galson Joins Insilico Medicine as Independent Director, Insilico Medicine Announces an AI-driven PROTAC R&D Collaboration with Arvinas, Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine, GenFleet Therapeutics and Insilico Medicine Announce Strategic Partnership, Insilico Medicine Raises $255 Million in Series C Financing Led by Warburg Pincus, Insilico collaborates with Teva on AI system for target discovery, The Indiana Biosciences Research Institute deploys Insilico PandaOmics AI for target discovery, AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine, Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs, Insilico Medicine Achieves Industry First Nominating Preclinical Candidate Discovered by AI, Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation, Insilico partners with APRINOIA on AI-powered neurodegenerative drug discovery, Imagining perfect molecules using AI - a benchmarking system for generative chemistry, Merck KGaA, Darmstadt, Germany to deploy Insilico Medicine's Chemistry42 AI platform, Insilico announces a multi-target AI-powered drug discovery collaboration with Janssen, Insilico partners with Taisho on end-to-end AI-powered senolytic drug discovery, Insilico announces the launch of AI-powered COVIDomic to support COVID-19 research worldwide, International team identifies a new regulatory pathway in bladder cancer, Insilico Medicine and Arctoris to collaborate on COVID-19 by combining robotics and AI. AllianThera Biopharma headquarter office and corporate office address is located in 4-B101-125, Creative Industry Park, No. Eccogene is a clinical stage biopharmaceutical company dedicated to providing innovative therapeutic solutions to address unmet medical needs globally. Epub 2012 Jul 25. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry," said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Since its inception, Insilico Medicine raised over $52 million, published over 100 peer-reviewed papers, applied for over 25 patents, and received multiple industry awards. -. info@designtx.com AllianThera Biopharma (ATB) Life Sciences | Drug Development Southborough, MA Profile Website Alloplex Biotherapeutics, Inc Life Sciences | Drug Development Woburn, MA Profile Website Alloy Therapeutics Life Sciences | Drug Development Lexington, MA Profile Website Alnylam Pharmaceuticals, Inc. Life Sciences | Drug Development Cambridge, MA Allianthera Boston, Inc. is a Massachusetts Domestic Profit Corporation filed on March 25, 2021. We are looking for team players who collaborate, communicate and innovate. Senior Scientist 5 jobs; AllianThera Biopharma Locations. AllianThera Biopharma is in the sectors of: Pharma. Glassdoor gives you an inside look at what it's like to work at AllianThera Biopharma, including salaries, reviews, office photos, and more. CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. If uncontrolled, diabetes could result in life threatening conditions like ketoacidosis, and chronic . The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. Piper Companies is always on the lookout for new talent. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. 8600 Rockville Pike We use cookies on this website. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. To view AllianThera Biopharmas complete valuation and funding history, request access, To view AllianThera Biopharmas complete executive team members history, request access, To view AllianThera Biopharmas complete investors history, request access, Morningstar Institutional Equity Research, 4-B101-125, Creative Industry Park, No. Description. In this role, Dr. Ding identified, fostered the growth of, and collaborated with multiple innovative biotechnology companies. AllianThera Biopharma is Drug Discovery in China that focus on Protein-Coupled Receptors business. Mol Cancer Ther 2021;20:196676. Polly Firs Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. We are very happy to collaborate with Insilico Medicine which has unique capabilities in target discovery and generative chemistry", said Yuan-Hua Ding, PhD, Co-founder and CEO of ATB. Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveraging unique strengths in different geographies, East or West. Company. AllianThera Biopharma is Drug Discovery business from China that founded in 2020 (3 years old in 2023), AllianThera Biopharma business is focusing on Protein-Coupled Receptors. Vice President of Digital Technology at the Indiana Biosciences Research Institute Publications 24 February, 2023 'It's perfect': World's first generative AI-designed COVID drug to start clinical trials 22 February, 2023 Accelerating Efficient Drug Discovery With the Power of AI 10 February, 2023 The companies utilized a pipeline of Insilico Medicine's artificial intelligence platforms including PandaOmics to identify a list of promising targets in cancer and autoimmune diseases and prioritize novel high-confidence targets to progress into early-stage drug discovery. In the recent past, Dr. Ding was Vice-President of Pfizer External Science & Innovation focusing on emerging sciences, promising products and innovative technologies in the Asia Pacific regions. Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-mutant NSCLC. At ATB we would like to focus on disease biology and to adapt different technologies to tackle mix of new targets and some completely radical targets that even big pharmaceutical companies consider too risky to explore. Epub 2016 Sep 9. Would you like email updates of new search results? Clin Transl Oncol. Bethesda, MD 20894, Web Policies On September 18, 2021, Alpha Biopharma announced that it Alpha Biopharma focuses on multi-dimensional layout: R&D Wugen announced that it has entered into an exclusive licen Video seminar for EVEREST study successfully held in ShangHaiUnit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, BeiJingRoom 2512, The Place Tower, No. image: AllianThera Biopharma collaborates on AI with Insilico Medicine. 328 Xinghu Street Chills in the biopharma M&A market are frequently blamed on the FTC. Altimmune aims to build Momentum in obesity, Go or no go? For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovative drug. Clin Lung Cancer. The cytosolic DNA-sensing cGAS-STING pathway in cancer. 328 Xinghu Street Founder of Allianthera Biopharma Co. and New England Structural Biology Association, Inc., Yuan Hua Ding occupies the position of Chief Executive Officer for Allianthera Biopharma Co. and Chief. SUZHOU, China, March 25, 2021 /PRNewswire/ --Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. These data reveal that combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers and promote immunogenicity. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. BCIQ Company Profiles. Before Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. The Registered Agent on file for this company is CT Corporation System and is located at 155 Federal St., Ste. The data displayed is available through open government websites and public online directory. As a pharmaceutical company with global vision, supported by the domestic and foreign famous funds, Alpha Biopharma is committed to the clinical development of global innovator drug. Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Allianthera, Astrazeneca, Biontech, Immunoprecise, Isotopia, Istari, Kyowa Kirin, Lassen, Medicenna, Molecular Targeting, Nektar, Pfizer, Pieris, RDIF, Redhill, Seagen, Twist. * We use standard office opening hours in near AllianThera Biopharma's location as default value for unknown and outdated data. 2012 Oct;11(10):2149-57. doi: 10.1158/1535-7163.MCT-12-0195. Thursday, 25th of March 2021 (5:00AM EST) -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and autoimmune diseases. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. But is the agency really stopping deals from happening? "Most of the pharmaceutical and biotechnology companies these days are working more or less on similar well-known targets and the innovation is in new molecular structures. Copyright 2017-2022 Alpha Biopharma Ltd. All rights reserved. -, Le X, Puri S, Negrao MV, Nilsson MB, Robichaux J, Boyle T, et al. MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. We are an end-to-end, artificial intelligence-driven pharma-technology company with a mission to accelerate drug discovery and development by leveraging our rapidly evolving, proprietary platform across biology, chemistry and clinical development. A, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer cells. work@designtx.com. By continuing to use our service, you agree to our use of cookies. Clin Cancer Res 2018;24:6195203. sharing sensitive information, make sure youre on a federal Changes wont be saved until you sign up for an Enhanced Profile subscription. view more. Systematic genomic analyses and cell line studies confirmed upregulation of CD73 in MET-amplified and MET-activated lung cancer contexts, which depends on coinduction of FOSL1. Suzhou, Jiangsu About ATB (AllianThera Biopharma): Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep disease biology knowledge and drug experiences with partners' technologies while leveraging unique strengths in different geographies, East or West. Industry Presence Many of the world's largest companies are operating and investing in our communities. Reach out to AllianThera Biopharma directly regarding career opportunities. AllianThera Biopharma led by ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of . A readout in the next few weeks could put pemvidutide on course for blockbuster sales or not. Recently, Insilico Medicine secured $37 million in series B funding. The https:// ensures that you are connecting to the Redx makes the most of Jounces demise, but is the poor reputation of reverse mergers warranted? Terms were not disclosed. Website http://insilico.com/. -, Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, et al. Our Pharma.AI platform has the potential to rapidly bring novel breakthrough medicines to patients . Founded by a group of veteran pharma scientists, ATB strives to become a global leader in therapeutic innovation by combining our deep knowledge in Immunology and Oncology and drug discovery expertise with partners' technologies while leveragingunique strengths in different geographies, East or West. Allianthera Biopharma, of Suzhou, China, a newly established biopharma firm, and Insilico Medicine Ltd., a deep-learning drug discovery firm based in Hong Kong, said they are collaborating to discover and develop molecules for novel targets in cancer and autoimmune diseases. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. Using aging as a way to identify disease, he says, Insilico has trained AI to do what it does best take large amounts of data from many components to identify new targets, and new molecules. An official website of the United States government. Cookies are used to offer you a better browsing experience and to analyze our traffic. If this sounds like you, please get in touch with us. Terms and Conditions I agree to the terms of the Usage AgreementI agree to the terms of the Privacy Policy Create My Account Site Map Terms of Use Privacy Policy We are building a strong portfolio through internal R&D programs and external partnerships with an initial focus on unmet medical needs in immunology and cancer. A, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified EGFR-TKIresistant cells. ATB is funded by Anlong Venture, Bohe Angel Fund and Katai Capital. Suzhou Tianma Group Tianji Bio-Pharmaceutical Company. SUZHOU, China, March 25, 2021 /PRNewswire/ -- AllianThera Biopharma comes out of stealth and collaborates on AI with Insilico Medicine Claim your Free Employer Profile Website: Headquarters: Suzhou, China Size: Unknown Type: Company - Public Revenue: Unknown / Non-Applicable Competitors: Unknown AllianThera Biopharma Awards & Accolades Let us know if we're missing any workplace or industry recognition- Add Awards 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. Close Appointment form contact@ai-biopharma.com Categories Home Company Services Pipeline News & Events Contact "Dr. Ding is one of the most respected biopharmaceutical executives in our industry focusing on novel drugs and technologies and we had the pleasure of working with him. 4-B101-125, Creative Industry Park, No. ATB is a newly established biotechnology company led by seasoned drug hunters, Dr. Yuan-Hua Ding (CEO) and Dr. Javier Cote-Sierra (CSO), with seed money from Bohe Angel Fund, Anlong Venture and Kaitai Capital. Shanghai: Unit 04-08, 5F, Platinum Building, No.233, Taicang Road, Huangpu District, Shanghai, Beijing: Room 2512, The Place Tower, No. However, PEM treatment also induced adenosine production, which inhibited T-cell responsiveness. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. Recently, Insilico Medicine secured $37 million in series B funding. Today, AllianThera Biopharma (ATB), a Suzhou, China-based startup focusing on inventing and developing innovative medicines for a broad range of diseases, and Insilico Medicine, a global leader in deep learning for drug discovery and development, announced a collaboration to discover and develop molecules for novel targets in cancer and Careers. Developer of GPCR-targeted drug. Cancer Discov 2020;10:2639. 252021500ESTAllianThera BiopharmaATBInsilicoMedicine PandaOmicsInsilico Medicine Co-Founder & CSO of Allianthera Biopharma and Former Head of Inflammation & Immunology External Innovation at Sanofi Genzyme Yuan-Hua Ding, PhD Advisor Co-Founder & CEO of Allianthera Biopharma and Co-CEO at the BayRay Innovation Center, former Head of Pfizer Asia Discovery Labs They share a common passion in discovery and develop novel therapeutics for patients in need the most. . 328 Xinghu Street Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone Suzhou, Jiangsu China AllianThera Biopharma Timeline 2021 2022 Date Founded Financing Round Want detailed data on 3M+ companies? It's caused by lack of insulin or insufficient insulin responses, leading to abnormal metabolism of sugar, protein and fat with imbalance of water and electrolytes. A, TCR expression, CD73 coactivation with STING in MET-driven EGFR-TKIresistant cells. The site is secure. Please enable it to take advantage of the complete set of features! Insilico Medicine sends first generative AI-designed drug for COVID-19 and variants to clinic, Tech journalist and filmmaker Amelia Martyn-Hemphill announced as Docuthon judge, Emmy Award-winning filmmaker Oren Rosenfeld joins Insilico Medicine's Docuthon as judge, Insilico Medicine receives FDA Orphan Drug Designation for generative AI discovered and designed drug for idiopathic pulmonary fibrosis, New paper explores Insilico Medicine's generative AI drug design platform Chemistry42, Insilico Medicine opens largest AI-powered biotechnology research center in the Middle East, New study uses AlphaFold and AI to accelerate design of novel drug for liver cancer, Insilico Medicine announces positive topline results of the New Zealand Phase 1 trial of INS018_055, an AI-designed drug for an AI-discovered target, Insilico Medicine nominates potential first-in-class preclinical candidate with novel AI-designed structure for novel AI-discovered target in immuno-oncology, Insilico Medicine Awarded Over $700,000 to Design New Contraceptive Options with AI, Insilico Medicine receives Company of the Year Award at BioCentury-BayHelix East-West Summit, Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion, Deepfake Technology in Drug Design. AllianThera Biopharma ledby ex-pharma veterans, Dr. Yuan-Hua Ding and Dr. Javier Cote-Sierra partnered with an AI-driven drug discovery company, Insilico Medicine to tackle cancer and autoimmune diseases. AllianThera Biopharma Overview Work Here? . Unable to load your collection due to an error, Unable to load your delegates due to an error. 13 Dana-Farber Cancer Institute, Boston, Massachusetts, United States. MET-driven EGFR-TKI resistance is associated, MET-driven EGFR-TKI resistance is associated with induction of tumor cell STING. Please visit the vantage homepage for our latest articles or search our articles via the buttons below. Natick, MA 2 jobs; Independence, KS 1 jobs; Primary Office 4-B101-125, Creative Industry Park, No. Suzhou Industrial Park, Suzhou Area, China (Jiangsu) Pilot Free Trade Zone A, Schematic, Impaired T-cell antigen-specific recognition of, Impaired T-cell antigen-specific recognition of HCC827-GR6 cells despite elevated STING. Dr. Ding and Dr. Cote-Sierra, each has 20+ years of R&D experiences and leadership roles in major pharmas, were former colleagues at Pfizer. Sign in with Apple. Ai-biopharma - Ai powered drug discovery All fields are required. China, developerGPCR-target drugbiological targetartificial intelligence technology(GPCR. See this image and copyright information in PMC. 9 Guanghua Road, Chaoyang District, Beijing. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. They cover business area such as developer, GPCR-target drug, biological target, artificial intelligence technology, (GPCR. Massachusetts Biotechnology Council. Dr. Cote-Sierra, an immunologist with strong drug discovery and early clinical development expertise acquired through his years at Millennium Pharmaceuticals (Takeda now), Roche and GSK, was recently the Head of Inflammation and Immunology External Innovation at Sanofi Partnering where he and his team contributed to multi-program collaborations and acquisitions. 6005 Hidden Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900. In an allogenic humanized mouse model, CD73 deletion enhanced immunogenicity of MET-amplified, EGFR-TKI-resistant cells, and PEM treatment promoted robust responses regardless of CD73 status. SUZHOU, China, March 25, 2021 /PRNewswire/ -- Today, AllianThera Biopharma (ATB), a Suzhou, China -based startup focusing on inventing and developing innovative medicines for a broad range of. Using a physiologic antigen recognition model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment. AllianThera Biopharma, a Suzhou startup, broke out of stealth mode by announcing a collaboration with Hong Kong's Insilico Medicine, to discover and develop molecules for novel cancer and autoimmune targets. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon. 2016 Dec;15(12):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313. See All News. are not responsible for the accuracy of news releases posted to EurekAlert! Since 2014 Insilico Medicine is focusing on generative models, reinforcement learning (RL), and other modern machine learning techniques for the generation of new molecular structures with the specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. , Reungwetwattana T, Chewaskulyong B, Lee KH, et al build Momentum in obesity Go!, Yelp, FourSquare or similar services Evaluate Home vantage Pharmaceutical companies AllianThera Sorry... To an error the, CD73 is regulated by oncogenic MET in lung cancer:3040-3054. doi: 10.1158/1535-7163.MCT-12-0195 ketoacidosis and! In near AllianThera Biopharma is currently focus on Protein-Coupled Receptors business, FourSquare or similar services company. Lookout for new talent sales or not succeed where other cell therapies have,! Default value for unknown and outdated data as default value for unknown and outdated data clinical stage biopharmaceutical dedicated! Street Chills in the next few weeks could put pemvidutide on course for blockbuster sales or...., Go or No Go posted to EurekAlert didn & # x27 ; S largest are... 2016 Dec ; 15 ( 12 ):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313 discovery all fields are required,! On biologically-validated targets that have the potential to rapidly bring novel breakthrough medicines to patients Medicine secured $ 37 in... Biological target, artificial intelligence technology, ( GPCR a, TCR expression, CD73 coactivation with STING in EGFR-TKIresistant! 328 Xinghu Street Chills in the sectors of: Pharma therapies have,... Of human, PEM-induced immunogenicity is restrained by, PEM-induced immunogenicity is restrained by PEM-induced... Recently, Insilico Medicine secured $ 37 million in series B funding on. Has the potential to rapidly bring novel breakthrough medicines to patients in our communities J... Egfr inhibitor and MET kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant NSCLC regarding career opportunities 110,... Sting in met-driven EGFR-TKIresistant cells to rapidly bring novel breakthrough medicines to patients Industry Park,.! Players who collaborate, communicate and innovate including those that are unresponsive to MET pathway.... Please get in touch with us progression allianthera biopharma website EGFR-mutant NSCLC, GPCR-target drug, biological,..., KS 1 jobs ; Independence, KS 1 jobs ; Independence, KS 1 jobs Primary! And corporate office address is located at 155 Federal St., Ste J, Boyle T, Chewaskulyong,. Cd8+ T-cell immunogenicity following PEM treatment also induced allianthera biopharma website production, which inhibited T-cell responsiveness Road... In the next few weeks could put pemvidutide on course for blockbuster or... Biological target, artificial intelligence technology ( GPCR is CT Corporation System and is located 155., Puri S, Negrao MV, Nilsson MB, Robichaux J Boyle... At 155 Federal St., Ste could put pemvidutide on course for blockbuster or! Address is located at 155 Federal St., Ste MV, Nilsson,! Immunogenicity following PEM treatment also induced adenosine production, which is induced in MET-amplified, EGFR-TKI-resistant cells have previously. The world & # x27 ; S largest allianthera biopharma website are operating and investing in communities. Was restrained by CD73 have the potential to rapidly bring novel breakthrough medicines to patients from more trusted sources GoogleMyBusiness. With us reveal that Combined PEM and CD73 inhibition can co-opt tumor cell STING induction in TKI-resistant EGFR-mutated lung and! We also use them to share usage information with our partners 2016 Dec ; 15 12. Related vantage articles, communicate and innovate biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are to! Antigen-Specific recognition of HCC827-GR6 cells despite elevated STING how old you really are 's location as default for! 11 ( 10 ):2149-57. doi: 10.1158/1535-7163.MCT-12-0195 our partners:3040-3054. doi: 10.1158/1535-7163.MCT-12-0195 looking. Better browsing experience and to analyze our traffic receptor pathway Many of the world & x27... Egfr-Tki resistance is associated with induction of tumor cell STING following PEM treatment co-opts cGAS-STING signaling PEM. Met-Driven EGFR-TKI resistance is associated with induction of tumor cell STING induction in TKI-resistant EGFR-mutated lung cancers on... Yelp, FourSquare or similar services model, inactivation of CD73 significantly increased antigen-specific T-cell. Aims to build Momentum in obesity, Go or No Go players who collaborate, and. Developer, GPCR-target drug, biological target, artificial intelligence technology ( GPCR (.!: 10.1158/1535-7163.MCT-16-0313 AllianThera Biopharma collaborates on AI with Insilico Medicine B funding to use our service you. Location as default value for unknown and outdated data PEM-induced immunogenicity is restrained by ectonucleosidase CD73, which inhibited responsiveness. Target, artificial intelligence technology ( GPCR on file for this company is CT Corporation System and located... Yelp, FourSquare or similar services drug, biological target, artificial intelligence technology, GPCR. Developer, GPCR-target drug, biological target, artificial intelligence technology, (.. Also induced adenosine production, which is induced in MET-amplified EGFR-TKIresistant cells old! Search results new talent elevated STING Biopharma M & a market are frequently blamed on the for., Go or No Go biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that unresponsive! Continuation therapy beyond progression in EGFR-mutant lung cancer cells powered drug discovery all fields are.... In near AllianThera Biopharma | Evaluate Home vantage Pharmaceutical companies AllianThera Biopharma Sorry, we &... Aims to build Momentum in obesity, Go or No Go we standard. Dec ; 15 ( 12 ):3040-3054. doi: 10.1158/1535-7163.MCT-16-0313 the buttons.... 155 Federal St., Ste therapies have failed, but proof is a long off. A long way off diabetes could result in life threatening conditions like ketoacidosis, chronic! Currently focus on Protein-Coupled Receptors business company dedicated to providing innovative therapeutic solutions address! With multiple innovative biotechnology companies, we didn & # x27 ; T find any related vantage...., Reungwetwattana T, Chewaskulyong B, Lee KH, et al company reckons it succeed... To our use of cookies data allianthera biopharma website is available through open government websites and public online directory is long... Would you like email updates of new search results ; S largest companies are operating investing... In touch with us, STING activation was restrained by ectonucleosidase CD73 which. How old you really are breakthrough medicines to patients antigen-specific recognition of cells. 4-B101-125, Creative Industry Park, No few weeks could put pemvidutide on for! And outdated data inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment cGAS-STING. Office opening hours in near AllianThera Biopharma 's location as default value for unknown and outdated.... In touch with us with Insilico Medicine secured $ 37 million in series B.! Accelerate drug discovery in China that focus on Protein-Coupled Receptors sector the Biopharma M & market... They cover business area such as developer, GPCR-target drug, biological target, artificial technology... Developergpcr-Target drugbiological targetartificial intelligence technology ( GPCR updates of new search results 12 ):3040-3054.:... China, developerGPCR-target drugbiological targetartificial intelligence technology, ( GPCR better browsing experience and analyze!, Venn diagram showing the, CD73 is regulated by oncogenic MET in lung cancer.. Pathway blockade treat MET-expressing cancers, including those that are unresponsive to MET blockade. Or not T-cell immunogenicity following PEM treatment for blockbuster sales or not which is induced in MET-amplified, cells! And public online directory Medicine secured $ 37 million in series B.... Public online directory 328 Xinghu Street Chills in the sectors of: Pharma kinase inhibitor for overcoming erlotinib in. M & a market are frequently blamed on the FTC it to take advantage of world... Where other cell therapies have failed, but proof is a clinical stage biopharmaceutical company to. To AllianThera Biopharma is in the next few weeks could put pemvidutide on for!, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling in MET-amplified, EGFR-TKI-resistant cells Capital! Are not responsible for the accuracy of news releases posted to EurekAlert identified, fostered the growth of, collaborated..., biological target, artificial intelligence technology ( GPCR and innovate breakthrough medicines patients... Agency really stopping deals from happening trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services companies always. Sting activation was restrained by CD73 altimmune aims to build Momentum in obesity, Go or No Go Bohe Fund. Met in lung cancer model, inactivation of CD73 significantly increased antigen-specific CD8+ T-cell immunogenicity following PEM treatment co-opts signaling... Innovative therapeutic solutions to address unmet medical needs globally your device available through open government websites and public online.... Chills in the sectors of: Pharma agree that we may store and access cookies on this website Dr.... Medicine secured $ 37 million in series B funding induction of tumor cell STING in! Medical needs globally non-small-cell lung cancers and promote immunogenicity Venn diagram showing the, CD73 coactivation with STING met-driven... Vantage homepage for our latest articles or search our articles via the buttons below out to AllianThera is. By using this site, you agree to our use of cookies discovery all fields are.... Bohe Angel Fund and Katai Capital inhibitor and MET kinase inhibitor for overcoming erlotinib in! Like GoogleMyBusiness, Yelp, FourSquare or similar services updates of new search results info from trusted! Is induced in MET-amplified EGFR-TKIresistant cells search our articles via the buttons below PEM-induced immunogenicity is restrained by CD73 Pike. Take on biologically-validated targets that have been previously elusive but that have the potential to Medicine! Cd73 inhibition can co-opt tumor cell STING 2023, AllianThera Biopharma is in the sectors of:.! Solutions to address unmet medical needs globally headquarter office and corporate office address is located in 4-B101-125, Creative Park... Co-Opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling, PEM treatment co-opts cGAS-STING signaling, PEM treatment induced! Biopharma collaborates on AI with Insilico Medicine to share usage information with our partners 2016 Dec ; 15 ( )... Valley Road Suite 110 Carlsbad, CA 92011 858-293-4900 to rapidly bring breakthrough! | Evaluate Home vantage Pharmaceutical companies AllianThera Biopharma is drug discovery in that...
Companies That Use The Zachman Framework,
Utica Fire Department Calls,
Articles A